Sodium Oxybate (GHB) – Kodiac biolabs

Our opinion on this compoundFederally scheduled

57/100

Canonical GHB receptor probe and approved narcolepsy drug with serious regulatory burden and limited novelty

Look, sodium oxybate is a genuinely weird compound to score because it lives in two regulatory worlds simultaneously. As Xyrem its Schedule III; as free-base GHB its Schedule I. That dual status isnt just an administrative footnote for a bench scientist. It shapes everything about sourcing, handling, institutional approval, and the realistic scope of an investigator’s research program. We’re not penalizing it for being controlled, but we’re not pretending that friction doesn’t exist either.

The pharmacology itself is interesting in a way that doesn’t fully show up until you dig into the receptor biology. GHB has two binding targets: a high-affinity, low-capacity GHB-specific receptor (Kd around 50 nM) and low-affinity GABA-B (Ki around 5 mM). At clinically relevant doses, GABA-B dominates the functional output, but the GHB receptor is a genuinely understudied piece of neuropharmacology. It’s not GABA-B, its not an opioid receptor, its not something well-mapped by standard psychopharmacology toolsets. If you’re trying to untangle GHB receptor-specific signaling from GABA-B contributions, sodium oxybate is essentially the only game in town. That gives it real probe value that pure mechanism scores alone dont fully capture.

The evidence base is solid by research-library standards. Xyrem went through multiple Phase 3 RCTs for narcolepsy and has a decade-plus of post-approval pharmacovigilance. The slow-wave sleep consolidation effect is one of the cleaner mechanistic demonstrations in clinical sleep pharmacology. European data on alcohol dependence is messier and more contested, but there’s a real multi-lab literature there, not just a single consortium claiming results nobody else can replicate.

What drags the score down is novelty, and honestly that’s appropriate. This is not a compound where a serious bench scientist is going to find white space easily. The narcolepsy mechanism is well-characterized. The GABA-B angle has baclofen as a cleaner alternative for most purposes. The alcohol dependence angle is still alive but crowded with competing pharmacological approaches. If your research program requires specifically interrogating GHB receptor biology, sodium oxybate is indispensable. If your program only tangentially touches it, the regulatory cost isnt worth it when better-characterized GABA-B probes are on the shelf.

We think this one sits around the 57 range: too mature and too well-understood to score higher on novelty, but too pharmacologically unique and too clinically validated to score lower. The GHB receptor remains one of the weirder and less-answered questions in CNS pharmacology. That keeps it above pure workhorse territory.

Novelty: 30
Mechanism promise: 52
In-category differentiation: 60
Evidence quality: 72
Translational signal: 74
Research bench value: 65

Rationale Calculated overall of 57 sits below both the Schedule III cap (75) and Schedule I cap (65), so no cap binds; the score reflects a mature approved drug with genuine bench utility as the only pharmacological handle on GHB receptor biology, but low novelty and a dual scheduling status that creates significant access friction for investigators.

GHB receptor agonist / GABA-B partial agonist

Sodium gamma-hydroxybutyrate; an endogenous neurotransmitter and prescription medication for narcolepsy and (controversially) alcoholism.

Abstract

Sodium oxybate (sodium 4-hydroxybutanoate, GHB; CAS 502-85-2; molecular formula C4H7NaO3; molecular weight 126.09) is the sodium salt of gamma-hydroxybutyrate, an endogenous short-chain fatty acid neurotransmitter and metabolite of GABA. The compound binds two distinct receptors: high-affinity GHB receptors (Kd approximately 50 nM, low capacity) and low-affinity GABA-B receptors (Ki approximately 5 mM, high capacity); pharmacologically meaningful effects at clinical doses are predominantly GABA-B-mediated. Approved indications: narcolepsy with cataplexy and excessive daytime sleepiness; clinical effect involves consolidation of slow-wave sleep. Used in some European countries (notably Italy, France) for alcohol withdrawal and dependence treatment. Schedule III when prescribed as Xyrem; Schedule I as illicit GHB. The narrow therapeutic index makes overdose easy and dangerous; recreational misuse with predatory drug-facilitated assault has been a significant public health issue. Plasma half-life is approximately 0.5 to 1 hour. Used as the canonical GHB receptor and GABA-B partial agonist in academic neuroscience.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-346Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.